UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Sells 1,865,335 Shares of Ginkgo Bioworks Holdings, Inc. (NYSE:DNA)

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC cut its position in Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) by 98.1% during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The firm owned 36,249 shares of the company’s stock after selling 1,865,335 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC’s holdings in Ginkgo Bioworks were worth $295,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently made changes to their positions in DNA. Algert Global LLC acquired a new stake in Ginkgo Bioworks during the 2nd quarter worth $36,000. Wellington Wealth Strategies LLC. bought a new stake in shares of Ginkgo Bioworks in the second quarter worth about $41,000. Forbes J M & Co. LLP acquired a new stake in shares of Ginkgo Bioworks during the third quarter worth about $1,019,000. BNP Paribas Financial Markets bought a new position in shares of Ginkgo Bioworks during the 3rd quarter valued at about $1,287,000. Finally, PFG Investments LLC bought a new position in shares of Ginkgo Bioworks during the 3rd quarter valued at about $1,541,000. 78.63% of the stock is owned by institutional investors.

Ginkgo Bioworks Stock Up 15.3 %

DNA stock opened at $10.08 on Friday. The stock’s 50-day moving average price is $8.56. Ginkgo Bioworks Holdings, Inc. has a fifty-two week low of $5.26 and a fifty-two week high of $74.00. The firm has a market capitalization of $579.39 million, a PE ratio of -0.77 and a beta of 1.17.

Wall Street Analyst Weigh In

Separately, TD Cowen raised their target price on shares of Ginkgo Bioworks from $3.00 to $10.00 and gave the stock a “buy” rating in a report on Friday, September 20th. Three research analysts have rated the stock with a sell rating, one has assigned a hold rating and one has assigned a buy rating to the company. According to MarketBeat, the stock has an average rating of “Hold” and an average target price of $4.58.

Ginkgo Bioworks Company Profile

Ginkgo Bioworks Holdings, Inc, together with its subsidiaries, develops platform for cell programming in the United States. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. It serves pharma and biotech, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries.